NYXH Investors Have Opportunity to Join Nyxoah S.A. Fraud Investigation with the Schall Law Firm

Core Viewpoint - The Schall Law Firm is investigating Nyxoah S.A. for potential violations of securities laws related to misleading statements and undisclosed information regarding the FDA's approval process for the Genio® system [1][2]. Group 1: Investigation Details - The investigation centers on whether Nyxoah issued false or misleading statements or failed to disclose critical information to investors [2]. - On March 25, 2025, Nyxoah announced that the FDA issued an Approvable Letter for its Pre-Market Approval application for the Genio® system, indicating that the application substantially meets regulatory requirements [2]. - Analysts noted that this announcement may lead to a delay in the commercial launch of the Genio® system, resulting in a significant drop of over 21.3% in Nyxoah's share price the following day [2]. Group 2: Legal Representation - The Schall Law Firm is representing investors globally and specializes in securities class action lawsuits and shareholder rights litigation [3]. - Shareholders who have suffered losses are encouraged to contact the firm for a free discussion of their rights [3].